A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Dong Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Beijing Hospital Authority.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
To evaluate the effect of secondary cytoreductive surgery (SeCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer patients.
Methods
This retrospective study analyzed a prospective database. We collected information of 389 patients who were diagnosed with recurrent epithelial ovarian cancer. All patients underwent SeCRS with or without HIPEC. Overall survival and progression‐free survival (PFS) were used to evaluate the treatment effectiveness.
Results
Of the 389 patients collected, 123 underwent primary or interval cytoreductive surgery at initial treatment and SeCRS at recurrence (Group A), 130 underwent primary or interval cytoreductive surgery at initial and SeCRS plus HIPEC at recurrence (Group B), and 136 underwent primary or interval cytoreductive surgery plus HIPEC at initial and SeCRS plus HIPEC at recurrence (Group C). The median overall survival for Groups A, B, and C were 49.1 months (95% confidence interval [CI]: 47.6–50.5), 56.0 months (95% CI: 54.2–57.7), and 64.4 months (95% CI: 63.1–65.6), respectively. The median PFS for Groups A, B, and C were 13.1 months (95% CI: 12.6–13.5), 15.0 months (95% CI: 14.2–15.7), and 16.8 months (95% CI: 16.1–17.4), respectively. There were no significant difference in incidence and grade of adverse events among groups.
Conclusions
This study suggested that SeCRS plus HIPEC followed by chemotherapy resulted in longer overall survival and PFS than only SeCRS followed by chemotherapy in patients with recurrent ovarian cancer, especially in patients who were treated with repeat HIPEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing, People's Republic of China.
- Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing, People's Republic of China.
ORCID-Profile: Dong Yang, Wenpei Bai
Förderung
- Beijing Hospital Authority
Zitieren
APA
Yang, D., Zhang, Y., Gong, P., Liu, F., Gan, Y., & Bai, W. (2023). A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15673
Vancouver
Yang D, Zhang Y, Gong P, Liu F, Gan Y, Bai W. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15673
BibTeX
@article{Yang2023,
author = {Yang, Dong and Zhang, Yanbin and Gong, Ping and Liu, Feiran and Gan, Yale and Bai, Wenpei},
title = {A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15673}
}
EUVIMED